# Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

> **NCT00323739** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 80 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00323739
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-11
- **Final completion:** 2011-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323739, "Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00323739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*